{
    "data": [
        {
            "id": "69a0c42824c37e0001bbc783",
            "title": "MARA Holdings Stock Surges On Data Center Development Deal With Starwood",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>MARA Holdings Inc</strong> <a class=\"ticker-link\" data-exchange=\"NASDAQ\" data-ticker=\"MARA\" href=\"https://www.benzinga.com/quote/MARA\" rel=\"noopener\" target=\"_blank\">(NASDAQ:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/MARA\" target=\"_blank\">MARA</a>)<!-- --> shares are rising in extended trading on Thursday after the company reported fourth-quarter results and announced an agreement to convert facilities into <a href=\"https://www.benzinga.com/pressreleases/26/02/g50910407/mara-announces-strategic-partnership-with-starwood-to-accelerate-delivery-of-cutting-edge-hypersca\" target=\"_blank\">digital infrastructure sites</a>.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>MARA Holdings shares are powering higher. <a href=\"https://www.benzinga.com/quote/MARA\" rel=\"noreferrer noopener\" target=\"_blank\">Why is MARA stock up today?</a></strong></li>\n</ul><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\"><strong>MARA Misses Estimates In Q4</strong></h2><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">MARA said it mined 2,011 Bitcoin in the fourth quarter and purchased 1,670 as part of its broader Bitcoin treasury strategy.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\"><strong>MARA Partners With Starwood</strong></h2><!--/$--><!--$--><p class=\"block core-block\">MARA Holdings entered into a strategic agreement with Starwood Capital Group to enable the conversion and expansion of select MARA sites into digital infrastructure capable of meeting the growing demand from enterprise, hyperscale and AI customers.</p><!--/$--><!--$--><p class=\"block core-block\">The companies said they expect to deliver approximately one gigawatt of near-term IT capacity with a pathway to more than 2.5 gigawatts. </p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">“MARA’s power-rich sites give customers what they need most: predictable access to energy at scale,” said <strong>Fred Thiel</strong>, chairman and CEO of MARA Holdings.</p><!--/$--><!--$--><p class=\"block core-block\">“Our partnership with Starwood will allow us to turn that power certainty into capacity certainty, so customers can run diverse workloads close to their data and users. This joint venture structure also gives us a more capital-efficient way to accelerate the buildout of digital infrastructure across our portfolio.”</p><!--/$--><!--$--><p class=\"block core-block\">MARA executives will discuss the fourth quarter and likely provide more information on the data center deal on a conference call at 5 p.m. ET.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\"><strong>MARA Shares Move Higher</strong></h2><!--/$--><!--$--><p class=\"block core-block\"><strong>MARA Price Action:</strong> <a href=\"http://benzinga.com/quote/mara\" rel=\"noreferrer noopener\" target=\"_blank\">MARA Holdings shares</a> were up 15.50% in Thursday's after-hours session, trading at $9.76 at the time of publication, according to <a href=\"http://pro.benzinga.com/\" rel=\"noreferrer noopener\" target=\"_blank\">Benzinga Pro</a>.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Image: Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50915382\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/26/Livingston-Highlights-Bitcoin-Gains.jpeg",
            "link": "https://www.benzinga.com/trading-ideas/movers/26/02/50915382/mara-holdings-stock-surges-on-data-center-development-deal-with-starwood",
            "pub_date": "2026-02-27 06:07:40",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a0c49624c37e0001bbc7c5",
            "title": "Gold Is Sending A Message We Haven&#39;t Heard Since 2008",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">An expression of strength not seen since early 2008 has quietly returned<a href=\"https://www.benzinga.com/etfs/broad-u-s-equity-etfs/26/02/50905025/ai-driven-sector-rotation-wall-street-why-energy-outperforms-tech-2026-goldman-halo-trade\" target=\"_blank\"> to the market.</a></p><!--/$--><!--$--><p class=\"block core-block\">Gold – as tracked by the <strong>SPDR Gold Shares</strong> <a class=\"ticker-link\" data-exchange=\"ARCA\" data-ticker=\"GLD\" href=\"https://www.benzinga.com/quote/GLD\" rel=\"noopener\" target=\"_blank\">(NYSE:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/GLD\" target=\"_blank\">GLD</a>)<!-- --> – has now outperformed the S&amp;P 500 Index for seven consecutive months — the longest streak since February 2008.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">That date should not be dismissed as a coincidence.</p><!--/$--><!--$--><p class=\"block core-block\">In early 2008, the global financial crisis had not yet reached its dramatic climax. </p><!--/$--><!--$--><p class=\"block core-block\">Lehman Brothers would not collapse until September. Equity markets had not fully priced in systemic failure. Policymakers still projected stability.</p><!--/$--><!--$--><p class=\"block core-block\">But beneath the surface, stress was already spreading.</p><!--/$--><!--$--><p class=\"block core-block\">Gold noticed first.</p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">February 2008: Calm Before The Collapse</h2><!--/$--><!--$--><p class=\"block core-block\">In February 2008, the narrative was still relatively contained.</p><!--/$--><!--$--><p class=\"block core-block\">The crisis was widely described as a \"housing problem.\" Subprime mortgages were deteriorating. </p><!--/$--><!--$--><p class=\"block core-block\">Credit markets were tightening. Major banks were taking write-downs.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><p class=\"block core-block\">But most investors believed the damage was isolated to subprime and that large financial institutions were adequately capitalized. </p><!--/$--><!--$--><p class=\"block core-block\">The <strong>Vanguard Real Estate ETF</strong> <a class=\"ticker-link\" data-exchange=\"ARCA\" data-ticker=\"VNQ\" href=\"https://www.benzinga.com/quote/VNQ\" rel=\"noopener\" target=\"_blank\">(NYSE:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/VNQ\" target=\"_blank\">VNQ</a>)<!-- --> traded about 30% below its record high reached a year earlier. A selloff, yes — but nothing like the brutal 80% peak-to-trough collapse it ultimately endured by March 2009.</p><!--/$--><!--$--><p class=\"block core-block\">Treasury yields had been drifting lower since mid-2007, yet they stayed above 3.2% until November 2008 — reflecting a market that anticipated a mild slowdown, not the systemic collapse that ultimately followed.</p><!--/$--><!--$--><p class=\"block core-block\">Those assumptions would prove catastrophically wrong.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Why The 2026 Parallel Matters</h2><!--/$--><!--$--><p class=\"block core-block\">Today's environment looks very different on the surface. There is no housing crash. No visible banking panic.</p><!--/$--><!--$--><p class=\"block core-block\">Yet gold is once again outperforming equities in a way not seen since 2008. </p><!--/$--><!--$--><p class=\"block core-block\">That raises an uncomfortable question: What is the market quietly hedging against?</p><!--/$--><!--$--><p class=\"block core-block\">Gold has historically recognized fragility before narratives catch up. </p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">In the early 1970s, gold began climbing before inflation fully erupted — and it surged again ahead of the second inflation wave later in the decade.</p><!--/$--><!--$--><p class=\"block core-block\">In 2008, gold's strength came months before markets recognized how fragile the financial system had become.</p><!--/$--><!--$--><p class=\"block core-block\">In 2026, the fault line may not be housing or subprime credit — but in the software sector. </p><!--/$--><!--$--><p class=\"block core-block\">The <strong>iShares Expanded Tech-Software Sector ETF</strong> <a class=\"ticker-link\" data-exchange=\"ARCA\" data-ticker=\"IGV\" href=\"https://www.benzinga.com/quote/IGV\" rel=\"noopener\" target=\"_blank\">(NYSE:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/IGV\" target=\"_blank\">IGV</a>)<!-- --> is just 30% below its record highs set last year – sound familiar?</p><!--/$--><!--$--><p class=\"block core-block\">For more than a decade, software has been treated as structurally insulated.</p><!--/$--><!--$--><p class=\"block core-block\">High margins. Recurring revenue. Asset-light scalability. Minimal capital intensity. Global reach.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">These companies did not require factories or balance sheet leverage to grow. Their primary inputs were talent and code. As a result, they commanded some of the richest valuation multiples in modern market history.</p><!--/$--><!--$--><p class=\"block core-block\">But those valuations were built on a key assumption: that competitive moats would remain durable and that operating margins would persist at historically elevated levels.</p><!--/$--><!--$--><p class=\"block core-block\">Artificial Intelligence is now testing that assumption.</p><!--/$--><!--$--><p class=\"block core-block\">Just as housing was once assumed to be contained, today the market still believes AI-driven disruption will be efficiently absorbed and productivity-enhancing without destabilizing side effects.</p><!--/$--><!--$--><p class=\"block core-block\">But transitions between economic regimes are rarely smooth.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Photo: Shutterstock</em></p><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50915441\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/26/Shiny-Gold-Ingot-On-Nuggets--Top-View.jpeg",
            "link": "https://www.benzinga.com/markets/commodities/26/02/50915441/gold-is-sending-a-message-we-havent-heard-since-2008",
            "pub_date": "2026-02-27 06:09:30",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a0c2af24c37e0001bbc598",
            "title": "NovoCure Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">4 analysts have expressed a variety of opinions on NovoCure (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/NVCR\" target=\"_blank\">NVCR</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p><!--/$--><!--$--><p class=\"block core-block\">The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><!--/$--><!--$--><p class=\"block core-block\">In the assessment of 12-month price targets, analysts unveil insights for NovoCure, presenting an average target of $38.25, a high estimate of $49.00, and a low estimate of $18.00. This current average reflects an increase of 4.79% from the previous average price target of $36.50. </p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><h2 class=\"block core-block\">Analyzing Analyst Ratings: A Detailed Breakdown</h2><!--/$--><!--$--><p class=\"block core-block\">The standing of NovoCure among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p><!--/$--><!--$?--><template id=\"B:3\"></template><div></div><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h3 class=\"block core-block\">Key Insights:</h3><!--/$--><!--$?--><template id=\"B:4\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of NovoCure's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p><!--/$--><!--$--><p class=\"block core-block\"><a href=\"https://www.benzinga.com/quote/NVCR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage\" target=\"_blank\"><strong>Stay up to date on NovoCure analyst ratings.</strong></a></p><!--/$--><!--$--><p class=\"block core-block\">If you are interested in following small-cap stock news and performance <a href=\"https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage\" target=\"_blank\">you can start by tracking it here</a>.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"block core-block\">All You Need to Know About NovoCure</h2><!--/$--><!--$?--><template id=\"B:5\"></template><div></div><!--/$--><!--$--><h3 class=\"block core-block\">Financial Insights: NovoCure</h3><!--/$--><!--$--><p class=\"block core-block\"><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>Revenue Growth:</strong> NovoCure's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of <strong>7.81%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Net Margin:</strong> NovoCure's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-22.29%,</strong> the company may encounter challenges in effective cost control.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Return on Equity (ROE):</strong> NovoCure's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-10.79%,</strong> the company may face hurdles in achieving optimal financial performance.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Return on Assets (ROA):</strong> NovoCure's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-2.86%,</strong> the company may face hurdles in generating optimal returns from its assets.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Debt Management:</strong> NovoCure's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>2.34</strong>.</p><!--/$--><!--$--><h2 class=\"block core-block\">What Are Analyst Ratings?</h2><!--/$--><!--$--><p class=\"block core-block\">Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p><!--/$--><!--$--><p class=\"block core-block\">Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p><!--/$--><!--$--><p class=\"block core-block\">This article was generated by Benzinga's automated content engine and reviewed by an editor.</p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/11/06/analyst_ratings_8.jpg",
            "link": "https://www.benzinga.com/insights/analyst-ratings/26/02/50914966/novocure-stock-a-deep-dive-into-analyst-perspectives-4-ratings",
            "pub_date": "2026-02-27 06:01:22",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a0c2b724c37e0001bbc5ae",
            "title": "Acadia Healthcare Co Stock: A Deep Dive Into Analyst Perspectives (17 Ratings)",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">Ratings for Acadia Healthcare Co (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/ACHC\" target=\"_blank\">ACHC</a>) were provided by 17 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p><!--/$--><!--$--><p class=\"block core-block\">The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><!--/$--><!--$--><p class=\"block core-block\">The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $20.0, a high estimate of $28.00, and a low estimate of $13.00. A 15.54% drop is evident in the current average compared to the previous average price target of $23.68. </p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><h2 class=\"block core-block\">Deciphering Analyst Ratings: An In-Depth Analysis</h2><!--/$--><!--$--><p class=\"block core-block\">An in-depth analysis of recent analyst actions unveils how financial experts perceive Acadia Healthcare Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p><!--/$--><!--$?--><template id=\"B:3\"></template><div></div><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h3 class=\"block core-block\">Key Insights:</h3><!--/$--><!--$?--><template id=\"B:4\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Acadia Healthcare Co's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p><!--/$--><!--$--><p class=\"block core-block\"><a href=\"https://www.benzinga.com/quote/ACHC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage\" target=\"_blank\"><strong>Stay up to date on Acadia Healthcare Co analyst ratings.</strong></a></p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"block core-block\">Delving into Acadia Healthcare Co's Background</h2><!--/$--><!--$--><p class=\"block core-block\">Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.</p><!--/$--><!--$--><h3 class=\"block core-block\">Acadia Healthcare Co: Delving into Financials</h3><!--/$--><!--$--><p class=\"block core-block\"><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>Revenue Growth:</strong> Over the 3M period, Acadia Healthcare Co showcased positive performance, achieving a revenue growth rate of <strong>4.41%</strong> as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Net Margin:</strong> Acadia Healthcare Co's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>4.26%,</strong> the company showcases strong profitability and effective cost management.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>1.17%,</strong> the company showcases effective utilization of equity capital.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Return on Assets (ROA):</strong> Acadia Healthcare Co's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.57%,</strong> the company may face hurdles in achieving optimal financial performance.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Debt Management:</strong> Acadia Healthcare Co's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.78</strong>.</p><!--/$--><!--$--><h2 class=\"block core-block\">The Core of Analyst Ratings: What Every Investor Should Know</h2><!--/$--><!--$--><p class=\"block core-block\">Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p><!--/$--><!--$--><p class=\"block core-block\">Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p><!--/$--><!--$--><p class=\"block core-block\">This article was generated by Benzinga's automated content engine and reviewed by an editor.</p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/11/06/analyst_ratings_7.jpg",
            "link": "https://www.benzinga.com/insights/analyst-ratings/26/02/50914984/acadia-healthcare-co-stock-a-deep-dive-into-analyst-perspectives-17-ratings",
            "pub_date": "2026-02-27 06:01:31",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a0c05124c37e0001bbc1aa",
            "title": "MP Materials Stock Slips On Mixed Q4 Results",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>MP Materials Corp</strong> <a class=\"ticker-link\" data-exchange=\"NYSE\" data-ticker=\"MP\" href=\"https://www.benzinga.com/quote/MP\" rel=\"noopener\" target=\"_blank\">(NYSE:</a><a class=\"ticker\" href=\"https://www.benzinga.com/quote/MP\" target=\"_blank\">MP</a>)<!-- --> reported fourth-quarter financial results Thursday after the close. Here are the key highlights <a href=\"https://www.benzinga.com/pressreleases/26/02/b50909033/mp-materials-reports-fourth-quarter-and-full-year-2025-results\" target=\"_blank\">from the quarter</a>. </p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong>MP Materials stock is trending. <a href=\"https://www.benzinga.com/quote/MP\" rel=\"noreferrer noopener\" target=\"_blank\">What’s driving MP shares?</a></strong></li>\n</ul><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\"><strong>MP Delivers Mixed Quarterly Results</strong></h2><!--/$--><!--$--><p class=\"block core-block\">MP Materials reported fourth-quarter revenue of $52.69 million, missing analyst <a href=\"http://benzinga.com/quote/mp/earnings\" rel=\"noreferrer noopener\" target=\"_blank\">estimates</a> of $67.38 million, according to <a href=\"http://pro.benzinga.com/\" rel=\"noreferrer noopener\" target=\"_blank\">Benzinga Pro</a>. The company reported fourth-quarter adjusted earnings of nine cents per share, beating analyst estimates for breakeven earnings.</p><!--/$--><!--$--><p class=\"block core-block\">Total revenue was down 14% on a year-over-year basis after the company ceased all sales of its products to China in support of its domestic supply chain objectives.</p><!--/$--><!--$--><div class=\"sc-jHrKIi gTZsSs\"></div><!--/$--><!--$--><p class=\"block core-block\">MP said it produced 718 metric tons of NdPr oxide in the quarter, up 74% year-over-year, and 50,692 metric tons of rare earth concentrate, up 12% year-over-year. </p><!--/$--><!--$--><p class=\"block core-block\">“Our landmark partnership with the U.S. Department of War, together with our agreement with Apple to deliver scaled recycling and magnetics capabilities, anchors a durable platform to accelerate growth and extend our vertically integrated advantage,” said <strong>James Litinsky</strong>, founder, chairman and CEO of MP Materials.</p><!--/$--><!--$--><p class=\"block core-block\">MP Materials ended the quarter with $1.83 billion in cash, cash equivalents and short-term investments.</p><!--/$--><!--$--><p class=\"block core-block\">MP Materials executives will further discuss the quarter on an earnings call scheduled for 5 p.m. ET.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\"><strong>MP Stock Moves Lower After The Bell</strong></h2><!--/$--><!--$--><p class=\"block core-block\"><strong>MP Price Action:</strong> <a href=\"http://benzinga.com/quote/MP\" rel=\"noreferrer noopener\" target=\"_blank\">MP Materials shares</a> were down 2.83% in after-hours on Thursday, trading at $58.30 at the time of publication, according to <a href=\"http://pro.benzinga.com/\" rel=\"noreferrer noopener\" target=\"_blank\">Benzinga Pro</a>.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Photo: courtesy of MP Materials.</em></p><!--/$--><!--$--><!--/$--><!--$--><div class=\"bz-optimizely-campaign bz-optimizely-campaign-bottom-50914157\" data-nosnippet=\"true\"></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2026/02/26/Screenshot-2025-04-21-at-2-30-46PM.png",
            "link": "https://www.benzinga.com/markets/earnings/26/02/50914157/mp-materials-stock-slips-on-mixed-q4-results",
            "pub_date": "2026-02-27 05:51:16",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        }
    ]
}